| Document And Entity Information | Nov. 03, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Document Period End Date | Nov. 03, 2022 |
| Entity Registrant Name | CinCor Pharma, Inc. |
| Entity Central Index Key | 0001868734 |
| Entity Emerging Growth Company | true |
| Securities Act File Number | 001-41201 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 36-4931245 |
| Entity Address, Address Line One | 230 Third Avenue |
| Entity Address, Address Line Two | 6th Floor |
| Entity Address, City or Town | Waltham |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02451 |
| City Area Code | 844 |
| Local Phone Number | 531-1834 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | true |
| Title of 12(b) Security | Common Stock, $0.00001 par value per share |
| Trading Symbol | CINC |
| Security Exchange Name | NASDAQ |
| Amendment Description | The Current Report on Form 8-K/A (this "Amended Form 8-K") amends the Current Report on Form 8-K filed by CinCor Pharma, Inc. (the "Company") on November 3, 2022 (the "Original Form 8-K"). On November 3, 2022, the Company issued a press release (the "Press Release") announcing its financial results and general corporate updates for the third quarter ended September 30, 2022, which Press Release was furnished as Exhibit 99.1 to the Original Form 8-K. The purpose of this Amended Form 8-K is to correct and clarify certain information contained in the Press Release. No other changes to the Original Form 8-K have been made. |
